Blocking molecular target could make more cancers treatable with PARP inhibitors

June 29, 2011 in Cancer

BOSTON--Researchers at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.

Currently, the role of PARP inhibitors has mainly been restricted to cancers whose cells lack functioning versions of the damage-repair proteins BRCA1 or BRCA2 -- chiefly certain breast and .

In a paper published online by Nature Medicine, Geoffrey Shapiro, MD, and colleagues report that the BRCA1 repair protein is dependent on another protein, CDK1, known primarily as a regulator of the cell division cycle. When the scientists blocked CDK1 in cancer cell lines and in a mouse model of lung cancer, BRCA1 function was disrupted, making them susceptible to being killed by a PARP inhibitor.

Because most types of tumors don't have a mutated BRCA1 protein, they are less likely to be affected by PARP inhibitor treatment. The new findings, said Shapiro, "suggest that by blocking CDK1, we can disable BRCA1 in many types of cancers and make them sensitive to a PARP inhibitor. It could extend the use of these drugs to a much larger group of patients."

Shapiro, who heads Dana-Farber's Early Drug Development Center, said a clinical trial combining a CDK1 blocker and a PARP inhibitor in a variety of solid tumors is being planned.

Cells are equipped to heal damage to their , which are constantly being nicked or broken by exposure to or randomly during cell division. , in addition, become adept at repairing potentially lethal caused by radiation and , and use their machinery to survive and grow uncontrollably.

A major thrust in cancer research currently is developing ways to disable tumor cells' repair toolkits to make them more vulnerable to DNA-damaging agents. PARP inhibitor drugs prevent from repairing less-serious damage to the DNA strands of ; if those cells happen to lack a normal BRCA protein, the damage becomes more serious and the cells can't repair it, and then the cells die.

Most types of cancer cells, however, have normal BRCA proteins, making PARP inhibitors less effective. The Dana-Farber scientists sought a way to get around this and convert "BRCA-competent" tumor cells to "BRCA-less" cells that would be sensitive to anti-PARP drugs. Their studies revealed that BRCA1 molecules depend on the cell-cycle protein CDK1 to activate them.

CDK1 was previously identified as a regulator of the cell division cycle that can be overactive in many types of cancers, leading to unchecked growth. Currently several CDK1 inhibitors are in clinical trials as potential weapons against cancer. Shapiro and his colleagues implicated CDK1 for the first time as a control point in the DNA repair circuit that contains BRCA1. This suggested that blocking CDK1 activity might prevent BRCA1 from rescuing cancer cells from life-threatening DNA damage.

In a study involving lung cancer cells in the laboratory and implanted in mice, the researchers "found that if we deplete cancer cells of CDK1, we disrupt DNA repair and the cells become very sensitive to PARP inhibitors," said Shapiro, the senior author of the report. The researchers obtained their results using an existing CDK1- blocking drug along with a PARP inhibitor.

As a more stringent test, they tried the same strategy in mice genetically engineered with an oncogene, KRAS, that drives the most aggressive lung cancers in humans.

"We achieved tremendous responses in this mouse model," Shapiro said. "The survival curve of the animals nearly doubled."

In addition, he said, his team collaborated with pathologists at Brigham and Women's Hospital to show that the CDK1-PARP inhibiting strategy is selective for cancer cells -- normal cells were unaffected. Accordingly, Shapiro said, they did not observe significant toxicity from the drug treatment.

"We're quite excited about this and looking forward to evaluating this combination in clinical trials," said Shapiro.

Provided by Dana-Farber Cancer Institute

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts
  • A question about drug tolerance
    created20 hours ago
  • Poor nutrition leading to overeating?
    createdMay 23, 2012
  • Math and dyslexia?
    createdMay 21, 2012
  • portable metabolism meter?
    createdMay 21, 2012
  • Rare medical conditions on 20/20 tonight
    createdMay 18, 2012
  • "Good" Cholesterol in Doubt
    createdMay 17, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Childhood cancer scars survivors later in life

Scars left behind by childhood cancer treatments are more than skin-deep. The increased risk of disfigurement and persistent hair loss caused by childhood cancer and treatment are associated with emotional distress and reduced ...

Cancer created 3 minutes ago | popularity not rated yet | comments 0

Amino acid consumption associated with how fast cancer cells divide

For almost a century, researchers have known that cancer cells have peculiar appetites, devouring glucose in ways that normal cells do not. But glucose uptake may tell only part of cancer's metabolic story. Researchers from ...

Cancer created 12 minutes ago | popularity not rated yet | comments 0 | with audio podcast

Marked for destruction: Newly developed compound triggers cancer cell death

The BCL-2 protein family plays a large role in determining whether cancer cells survive in response to therapy or undergo a form of cell death known as apoptosis. Cells are pressured toward apoptosis by expression of pro-apoptotic ...

Cancer created 3 hours ago | popularity 5 / 5 (1) | comments 0

Thioridazine kills cancer stem cells in human while avoiding toxic side-effects of conventional cancer treatments

A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.

Cancer created 3 hours ago | popularity 4.7 / 5 (6) | comments 1 | with audio podcast

Study links mental health problems to poor prognosis in male cancer patients

Men suffering from psychiatric problems when diagnosed with cancer are more likely to die from the disease, according to a new study part-funded by the Wellcome Trust. The findings also reveal that those with ...

Cancer created 7 hours ago | popularity not rated yet | comments 0


Cyber exercise partners help you go the distance: Motivation gains can double

A new study testing the benefits of a virtual exercise partner shows the presence of a moderately more capable cycling partner can significantly boost the motivation – by as much as 100 percent – ...

Researchers identify protein necessary for behavioral flexibility

Researchers have identified a protein necessary to maintain behavioral flexibility, which allows us to modify our behaviors to adjust to circumstances that are similar, but not identical, to previous experiences. Their findings, ...

Boundary stops molecule right where it needs to be

A molecule responsible for the proper formation of a key portion of the nervous system finds its way to the proper place not because it is actively recruited, but instead because it can't go anywhere else.

Researcher calls for new approach to regulating probiotics

In today's Nature scientific journal Dr. Gregor Reid, Director of the Canadian R&D Centre for Probiotics at Lawson Health Research Institute and a scientist at Western University, calls for a Category Tree system to be imp ...

Male fertility genes discovered

A new study has revealed previously undiscovered genetic variants that influence fertility in men. The findings, published by Cell Press on May 24th in the American Journal of Human Genetics, shed much-needed light on hum ...

Knowing genetic makeup may not significantly improve disease risk prediction

Harvard School of Public Health (HSPH) researchers have found that detailed knowledge about your genetic makeup—the interplay between genetic variants and other genetic variants, or between genetic variants and environmental ...